After hours: March 26 at 7:57:25 PM EDT Loading Chart for MDGL ...

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company ...

Mets manager Carlos Mendoza informed reporters, including Anthony DiComo of MLB.com, that infielder Nick Madrigal will require surgery on his fractured left shoulder. The recovery from that ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges.

With sales of $103M in Q4 and $180M in its first nine months on the market, Madrigal's MASH treatment Rezdiffra has all the earmarks of a blockbuster.

New York Mets utility infielder Nick Madrigal will soon undergo shoulder surgery and likely miss the entirety of the upcoming 2025 season, manager Carlos Mendoza told reporters on Friday.

The New York Mets have lost an important depth piece, Nick Madrigal, who is expected to miss the entire 2025 season. As manager Carlos Mendoza shared with reporters on Friday, the utility ...

Bay Area journalist Alexis Madrigal’s book “The Pacific Circuit” is “a love letter to Oakland” rooted in environmental and political justice. In “The Pacific Circuit,” author Alexis Madrigal ...

Ehra Madrigal and her businessman husband Tom Yeung could not seem to contain their joy as they announced her first pregnancy, which came about eight years after they tied the knot. Ehra flaunted ...

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...